Gamco Investors INC. ET AL Has $12.77 Million Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Gamco Investors INC. ET AL reduced its stake in Boston Scientific Corporation by 2.1%, owning 126,582 shares valued at approximately $12.77 million after selling 2,743 shares in the first quarter.
• Boston Scientific reported quarterly earnings of $0.75 EPS, exceeding estimates, with a revenue of $5.06 billion, marking a 22.8% year-over-year increase.
• Analysts have raised their price targets for Boston Scientific, with Raymond James setting a target of $124, and Citigroup raising its target to $125, reflecting positive sentiment towards the company's future performance.

Gamco Investors INC. ET AL reduced its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 126,582 shares of the medical equipment provider's stock after selling 2,743 shares during the quarter. Gamco Investors INC. ET AL's holdings in Boston Scientific were worth $12,770,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after buying an additional 226 shares during the period. Bank Pictet & Cie Europe AG increased its position in shares of Boston Scientific by 40.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after acquiring an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE raised its holdings in shares of Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after acquiring an additional 1,439 shares during the period. Integrated Wealth Concepts LLC lifted its position in Boston Scientific by 2.7% in the 4th quarter. Integrated Wealth Concepts LLC now owns 16,140 shares of the medical equipment provider's stock valued at $1,442,000 after acquiring an additional 417 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC boosted its stake in Boston Scientific by 0.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 19,691 shares of the medical equipment provider's stock worth $1,759,000 after purchasing an additional 178 shares during the period. Institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wells Fargo & Company lifted their price target on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. UBS Group lifted their target price on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Robert W. Baird upped their price target on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Citigroup reissued a "buy" rating and issued a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Finally, Barclays increased their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $117.50.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Down 0.2%

BSX traded down $0.19 during trading on Friday, reaching $105.56. 4,066,860 shares of the stock were exchanged, compared to its average volume of 5,967,270. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock's 50 day moving average price is $104.53 and its two-hundred day moving average price is $102.17. Boston Scientific Corporation has a twelve month low of $79.53 and a twelve month high of $108.94. The stock has a market cap of $156.41 billion, a P/E ratio of 62.83, a price-to-earnings-growth ratio of 2.55 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.